丽珠医药(01513.HK)：康奇塔单抗注射液上市许可申请获国家药监局受理

Core Viewpoint - Lijun Pharmaceutical's subsidiary, Zhuhai Lijun Monoclonal Antibody Biotechnology Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the registration application of the monoclonal antibody injection, Laikangqita, developed in collaboration with Beijing Xinkanghe Biological Pharmaceutical Technology Co., Ltd. [1] Group 1 - The acceptance notice was issued under the acceptance number CXSS2500144 [1]